MannKind Corporation (MNKD) shares surged 6.03% in after-hours trading on Wednesday, following the release of the company's better-than-expected fourth-quarter financial results.
The biopharmaceutical company reported an operating income of $26.495 million for the quarter ended December 31, 2024, compared to an operating loss in the year-ago period. Net income came in at $7.422 million, or $0.03 per basic share, significantly outperforming analysts' estimates.
The strong quarterly performance likely fueled investor optimism, driving MannKind's stock higher in extended trading hours. However, more details on the company's revenue, pipeline updates, and forward guidance will be needed to assess the sustainability of the after-hours rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.